<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Natera Inc — News on 6ix</title>
    <link>https://6ix.com/company/natera-inc</link>
    <description>Latest news and press releases for Natera Inc on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Wed, 22 Apr 2026 13:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/natera-inc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835a3e278dffbe2df10a67c.webp</url>
      <title>Natera Inc</title>
      <link>https://6ix.com/company/natera-inc</link>
    </image>
    <item>
      <title>Prospera™ Evidence in Heart and Lung Transplantation Featured Across 17 Presentations at ISHLT</title>
      <link>https://6ix.com/company/natera-inc/news/prosperatm-evidence-in-heart-and-lung-transplantation-featured-across-17-presentations-at-ishlt</link>
      <guid isPermaLink="true">https://6ix.com/company/natera-inc/news/prosperatm-evidence-in-heart-and-lung-transplantation-featured-across-17-presentations-at-ishlt</guid>
      <pubDate>Wed, 22 Apr 2026 13:00:00 GMT</pubDate>
      <description>AUSTIN, Texas, April 22, 2026--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced a broad body of evidence supporting its Prospera test at the 2026 International Society for Heart and Lung Transplantation (ISHLT) Annual Meeting.</description>
    </item>
    <item>
      <title>Natera Highlights Positive Interim Futility Analysis from Allogene Therapeutics’ MRD-Guided ALPHA3 Trial in Large B-Cell Lymphoma</title>
      <link>https://6ix.com/company/natera-inc/news/natera-highlights-positive-interim-futility-analysis-from-allogene-therapeutics-mrd-guided-alpha3-trial-in-large-b-cell-lymphoma</link>
      <guid isPermaLink="true">https://6ix.com/company/natera-inc/news/natera-highlights-positive-interim-futility-analysis-from-allogene-therapeutics-mrd-guided-alpha3-trial-in-large-b-cell-lymphoma</guid>
      <pubDate>Mon, 13 Apr 2026 12:00:00 GMT</pubDate>
      <description>AUSTIN, Texas, April 13, 2026--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today highlighted Allogene Therapeutics’ (NASDAQ: ALLO) interim futility analysis from its registrational ALPHA3 trial for cemacabtagene ansegedleucel (cema-cel), an investigational allogeneic anti-CD19 CAR T therapy, in first-line (1L) consolidation large B-cell lymphoma (LBCL).</description>
    </item>
    <item>
      <title>Judge Awards 30% Ongoing Royalty to Natera for its MRD-Related Patents</title>
      <link>https://6ix.com/company/natera-inc/news/judge-awards-30percent-ongoing-royalty-to-natera-for-its-mrd-related-patents</link>
      <guid isPermaLink="true">https://6ix.com/company/natera-inc/news/judge-awards-30percent-ongoing-royalty-to-natera-for-its-mrd-related-patents</guid>
      <pubDate>Thu, 09 Apr 2026 10:00:00 GMT</pubDate>
      <description>AUSTIN, Texas, April 09, 2026--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today provided an update on a recent decision issued by the United States District Court in the District of Delaware regarding Natera’s litigation with ArcherDx and Invitae.</description>
    </item>
    <item>
      <title>20 Abstracts at AACR Highlight Scale, Innovation and Clinical Impact of Natera’s Oncology Platform</title>
      <link>https://6ix.com/company/natera-inc/news/20-abstracts-at-aacr-highlight-scale-innovation-and-clinical-impact-of-nateras-oncology-platform</link>
      <guid isPermaLink="true">https://6ix.com/company/natera-inc/news/20-abstracts-at-aacr-highlight-scale-innovation-and-clinical-impact-of-nateras-oncology-platform</guid>
      <pubDate>Tue, 07 Apr 2026 04:00:00 GMT</pubDate>
      <description>Data from &gt;75,000 patients underscore advances in AI-driven virtual genomics, Signatera™-guided treatment monitoring, and continued expansion of MRD and</description>
    </item>
    <item>
      <title>SignateraTM MRD Identifies Breast Cancer Patients Who Can Forgo Surgery</title>
      <link>https://6ix.com/company/natera-inc/news/signateratm-mrd-identifies-breast-cancer-patients-who-can-forgo-surgery</link>
      <guid isPermaLink="true">https://6ix.com/company/natera-inc/news/signateratm-mrd-identifies-breast-cancer-patients-who-can-forgo-surgery</guid>
      <pubDate>Tue, 31 Mar 2026 04:00:00 GMT</pubDate>
      <description>Prospective study published in Clinical Cancer Research shows that women &gt;70 who tested Signatera MRD-negative could avoid surgery and remain</description>
    </item>
    <item>
      <title>Two Publications Highlight Clinical Utility of Signatera™ in Anal and Rectal Cancers</title>
      <link>https://6ix.com/company/natera-inc/news/two-publications-highlight-clinical-utility-of-signateratm-in-anal-and-rectal-cancers</link>
      <guid isPermaLink="true">https://6ix.com/company/natera-inc/news/two-publications-highlight-clinical-utility-of-signateratm-in-anal-and-rectal-cancers</guid>
      <pubDate>Mon, 16 Mar 2026 04:00:00 GMT</pubDate>
      <description>New findings show that Signatera status can help identify high-risk patients and inform non-operative management and surveillance strategies AUSTIN,</description>
    </item>
    <item>
      <title>MyOme Debuts Zenith™ Portfolio with Natera and Launches Long-Read Methylation Analysis at ACMG 2026</title>
      <link>https://6ix.com/company/natera-inc/news/myome-debuts-zenithtm-portfolio-with-natera-and-launches-long-read-methylation-analysis-at-acmg-2026-1</link>
      <guid isPermaLink="true">https://6ix.com/company/natera-inc/news/myome-debuts-zenithtm-portfolio-with-natera-and-launches-long-read-methylation-analysis-at-acmg-2026-1</guid>
      <pubDate>Thu, 12 Mar 2026 04:00:00 GMT</pubDate>
      <description>MENLO PARK, Calif., March 12, 2026 /PRNewswire/ -- MyOme, a leader in clinical whole-genome analysis, announced an advancement in rare disease diagnostics at</description>
    </item>
    <item>
      <title>Natera Announces Commercial Launch of Zenith™ Genomics for Rare Disease Diagnosis</title>
      <link>https://6ix.com/company/natera-inc/news/natera-announces-commercial-launch-of-zenithtm-genomics-for-rare-disease-diagnosis-5</link>
      <guid isPermaLink="true">https://6ix.com/company/natera-inc/news/natera-announces-commercial-launch-of-zenithtm-genomics-for-rare-disease-diagnosis-5</guid>
      <pubDate>Thu, 12 Mar 2026 04:00:00 GMT</pubDate>
      <description>New genomic testing solution designed to shorten diagnostic journeys for patients and families; supports efforts to reduce the economic and societal burden</description>
    </item>
    <item>
      <title>Signatera™ MRD Data at ASCO GU Highlights Potential Utility Across GU Cancers, Including for Bladder Preservation</title>
      <link>https://6ix.com/company/natera-inc/news/signateratm-mrd-data-at-asco-gu-highlights-potential-utility-across-gu-cancers-including-for-bladder-preservation</link>
      <guid isPermaLink="true">https://6ix.com/company/natera-inc/news/signateratm-mrd-data-at-asco-gu-highlights-potential-utility-across-gu-cancers-including-for-bladder-preservation</guid>
      <pubDate>Fri, 27 Feb 2026 15:05:00 GMT</pubDate>
      <description>AUSTIN, Texas, February 27, 2026--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced it will present new data in genitourinary malignancies at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), taking place February 26-28, 2026.</description>
    </item>
    <item>
      <title>Natera Reports Fourth Quarter and Full Year 2025 Financial Results</title>
      <link>https://6ix.com/company/natera-inc/news/natera-reports-fourth-quarter-and-full-year-2025-financial-results</link>
      <guid isPermaLink="true">https://6ix.com/company/natera-inc/news/natera-reports-fourth-quarter-and-full-year-2025-financial-results</guid>
      <pubDate>Thu, 26 Feb 2026 05:00:00 GMT</pubDate>
      <description>AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for</description>
    </item>
    <item>
      <title>Successful Readout of Prospective Phase 2 SINERGY Trial Supports SignateraTM MRD-Guided Treatment in Head and Neck Cancer</title>
      <link>https://6ix.com/company/natera-inc/news/successful-readout-of-prospective-phase-2-sinergy-trial-supports-signateratm-mrd-guided-treatment-in-head-and-neck-cancer</link>
      <guid isPermaLink="true">https://6ix.com/company/natera-inc/news/successful-readout-of-prospective-phase-2-sinergy-trial-supports-signateratm-mrd-guided-treatment-in-head-and-neck-cancer</guid>
      <pubDate>Tue, 24 Feb 2026 05:00:00 GMT</pubDate>
      <description>Interventional trial validates adaptive Signatera-guided treatment approach, achieving strong 63% response rate while reducing chemotherapy exposure in 74%</description>
    </item>
    <item>
      <title>Natera to Report its Fourth Quarter and Full Year Results on February 26, 2026</title>
      <link>https://6ix.com/company/natera-inc/news/natera-to-report-its-fourth-quarter-and-full-year-results-on-february-26-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/natera-inc/news/natera-to-report-its-fourth-quarter-and-full-year-results-on-february-26-2026</guid>
      <pubDate>Tue, 17 Feb 2026 05:00:00 GMT</pubDate>
      <description>AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will release</description>
    </item>
    <item>
      <title>Natera Launches EDEN Study on Early Risk Assessment for Preeclampsia and Adverse Pregnancy Outcomes</title>
      <link>https://6ix.com/company/natera-inc/news/natera-launches-eden-study-on-early-risk-assessment-for-preeclampsia-and-adverse-pregnancy-outcomes</link>
      <guid isPermaLink="true">https://6ix.com/company/natera-inc/news/natera-launches-eden-study-on-early-risk-assessment-for-preeclampsia-and-adverse-pregnancy-outcomes</guid>
      <pubDate>Fri, 06 Feb 2026 05:00:00 GMT</pubDate>
      <description>Large prospective study to evaluate a non-invasive prenatal screening test AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NASDAQ: NTRA), a global leader in</description>
    </item>
    <item>
      <title>Natera Submits Signatera™ CDx PMA to FDA</title>
      <link>https://6ix.com/company/natera-inc/news/natera-submits-signateratm-cdx-pma-fda-2026-02-02</link>
      <guid isPermaLink="true">https://6ix.com/company/natera-inc/news/natera-submits-signateratm-cdx-pma-fda-2026-02-02</guid>
      <pubDate>Mon, 02 Feb 2026 05:00:00 GMT</pubDate>
      <description>Application backed by landmark phase 3 data validating MRD-guided treatment in bladder cancer AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NASDAQ: NTRA), a</description>
    </item>
    <item>
      <title>Natera Announces Completion of Enrollment in Randomized ACES-EMB Trial in Heart Transplantation</title>
      <link>https://6ix.com/company/natera-inc/news/natera-announces-completion-enrollment-randomized-aces-emb-trial-heart</link>
      <guid isPermaLink="true">https://6ix.com/company/natera-inc/news/natera-announces-completion-enrollment-randomized-aces-emb-trial-heart</guid>
      <pubDate>Wed, 28 Jan 2026 05:00:00 GMT</pubDate>
      <description>ACES-EMB is the first randomized-controlled trial to compare dd-cfDNA surveillance to routine biopsy in organ transplantation, highlighting the benefits of</description>
    </item>
    <item>
      <title>Prospera™ Featured in Landmark Interventional Study Advancing Lung Transplant Care</title>
      <link>https://6ix.com/company/natera-inc/news/prosperatm-featured-in-landmark-interventional-study-advancing-lung-transplant-care</link>
      <guid isPermaLink="true">https://6ix.com/company/natera-inc/news/prosperatm-featured-in-landmark-interventional-study-advancing-lung-transplant-care</guid>
      <pubDate>Mon, 26 Jan 2026 05:00:00 GMT</pubDate>
      <description>New publication shows that Prospera-guided care helped &gt;75% of low-risk patients safely avoid routine transbronchial biopsies performed at 9 months AUSTIN,</description>
    </item>
    <item>
      <title>Natera Publishes Clinical Validation of Latitude™ Tissue-Free MRD Test in Colorectal Cancer</title>
      <link>https://6ix.com/company/natera-inc/news/natera-publishes-clinical-validation-latitudetm-tissue-free-mrd-test-colorectal</link>
      <guid isPermaLink="true">https://6ix.com/company/natera-inc/news/natera-publishes-clinical-validation-latitudetm-tissue-free-mrd-test-colorectal</guid>
      <pubDate>Wed, 21 Jan 2026 05:00:00 GMT</pubDate>
      <description>Study reports high sensitivity and specificity, enabling MolDX submission and path to reimbursement in CRC AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc.</description>
    </item>
    <item>
      <title>Natera’s Fetal Focus™ Single Gene NIPT (sgNIPT) Selected for Prestigious Oral Plenary Presentation at Society of Maternal Fetal Medicine (SMFM) Meeting</title>
      <link>https://6ix.com/company/natera-inc/news/nateras-fetal-focustm-single-gene-nipt-sgnipt-selected-prestigious-oral-plenary</link>
      <guid isPermaLink="true">https://6ix.com/company/natera-inc/news/nateras-fetal-focustm-single-gene-nipt-sgnipt-selected-prestigious-oral-plenary</guid>
      <pubDate>Tue, 20 Jan 2026 05:00:00 GMT</pubDate>
      <description>EXPAND clinical trial to be presented; data support Fetal Focus™ sgNIPT for inherited conditions AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NASDAQ:</description>
    </item>
    <item>
      <title>Natera Announces Next Breakthrough in MRD-Based Risk Stratification, Leveraging Multi-Modal AI Modeling</title>
      <link>https://6ix.com/company/natera-inc/news/natera-announces-next-breakthrough-mrd-based-risk-stratification-leveraging-multi</link>
      <guid isPermaLink="true">https://6ix.com/company/natera-inc/news/natera-announces-next-breakthrough-mrd-based-risk-stratification-leveraging-multi</guid>
      <pubDate>Tue, 13 Jan 2026 05:00:00 GMT</pubDate>
      <description>New AI-derived model integrates longitudinal ctDNA and clinical data with digital pathology and tumor sequencing data, to refine recurrence risk assessment</description>
    </item>
    <item>
      <title>Natera to Scale AI Foundation Models in Precision Medicine with NVIDIA</title>
      <link>https://6ix.com/company/natera-inc/news/natera-scale-ai-foundation-models-precision-medicine-nvidia-2026-01-12</link>
      <guid isPermaLink="true">https://6ix.com/company/natera-inc/news/natera-scale-ai-foundation-models-precision-medicine-nvidia-2026-01-12</guid>
      <pubDate>Mon, 12 Jan 2026 05:00:00 GMT</pubDate>
      <description>AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA testing and precision medicine, today announced a new</description>
    </item>
  </channel>
</rss>